Research programme: multiple sclerosis and optic neuritis based therapeutics - Conectus/Find Therapeutics
Alternative Names: Multiple sclerosis and optic neuritis based therapeutics - Conectus/Find TherapeuticsLatest Information Update: 24 Jun 2022
At a glance
- Originator Conectus Alsace; Find Therapeutics
- Class Eye disorder therapies; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple sclerosis; Optic neuritis
Most Recent Events
- 07 Jun 2022 Preclinical trials in Multiple sclerosis in Canada (unspecified route)
- 07 Jun 2022 Preclinical trials in Optic neuritis in Canada (unspecified route)